Annual revenue fell from KRW 132.1 billion in 2022 to KRW 122.5 billion in 2023 (down 7.2% year on year), KRW 119.8 billion in 2024 (down 2.3%) and KRW 100.8 billion in 2025 (down 15.8%).
Revenue declined for three consecutive years from 2023 to 2025, with 2022 the largest year and 2025 the smallest in the 2022–2025 period. Daily Pharm also reported that revenue has fallen for three straight years from a 2022 peak.
Operating profit dropped from KRW 4.77 billion in 2022 to KRW 2.05 billion in 2023 (down 57.1%) and KRW 755 million in 2024 (down 63.1%), before turning into an operating loss of KRW 2.28 billion in 2025.
Operating margin went from 3.6 percent in 2022 to 1.7 percent in 2023, 0.6 percent in 2024 and -2.3 percent in 2025.
Net income attributable to controlling shareholders swung from a loss of KRW 6.33 billion in 2022 to a profit of KRW 3.86 billion in 2023, rose to KRW 6.48 billion in 2024 (up 67.8%), and then fell back into a loss of KRW 233 million in 2025. Net income including non-controlling interests followed the same pattern.
The company attributes the 2025 loss partly to lower output and higher costs following the 2022 Sangsin-ri plant fire. Operating cash flow moved from -KRW 234 million in 2022 to KRW 7.02 billion in 2023, KRW 11.6 billion in 2024 and KRW 11.9 billion in 2025.
Total equity at the end of 2025 was KRW 206.9 billion, all attributable to controlling shareholders, against total liabilities of KRW 6.29 billion, a debt ratio of 3.0 percent.
Quarterly revenue went from KRW 24.3 billion in Q3 2025 to KRW 18.6 billion in Q4 2025 (down 23.6% quarter on quarter), then KRW 23.4 billion in Q1 2026 (up 26.3%), KRW 24.5 billion in Q2 (up 4.4%) and KRW 24 billion in Q3 2026 (down 1.9% quarter on quarter and down 1.3% year on year).
Quarterly operating results moved from an operating profit of KRW 165 million in Q3 2025 to an operating loss of KRW 1.3 billion in Q4 2025, and losses have continued through Q3 2026, four quarters in a row.
The operating losses were KRW 566 million in Q1 2026, KRW 912 million in Q2 (wider) and KRW 781 million in Q3 (narrower, a swing to loss from a year earlier).
Net income attributable to controlling shareholders was KRW 4.37 billion in Q2 2026, up 655.5% from the prior quarter, before a net loss of KRW 1.93 billion in Q3 2026. The divergence between an operating loss and positive net income in Q2 makes non-operating items and one-off factors the next point to check. Net income attributable to controlling shareholders over the last four quarters totals KRW 2.51 billion.